Future Retirement Success
  • Politics
  • Business
  • Investing
  • Stocks
  • Politics
  • Business
  • Investing
  • Stocks

Future Retirement Success

Politics

Bipartisan bill seeks to stop pharmacy middlemen from driving up drug costs for financial gain

by March 19, 2025
March 19, 2025

A bipartisan group of lawmakers is pushing to reform the incentive structure for Pharmacy Benefit Managers (PBMs), arguing that it drives up patient costs by encouraging them to favor higher-priced drugs while withholding potential savings.

Led by physician and GOP Iowa Rep. Mariannette Miller-Meeks, the group introduced the ‘Delinking Revenue from Unfair Gouging (DRUG) Act’ on Tuesday, requiring that PBMs in the commercial market only charge a flat fee for their services related to a specific prescription drug, versus letting them continue to charge a percentage of the drug price. 

PBMs are third-party intermediaries between insurance companies, drug manufacturers and pharmacies that serve to control drug prices and access. The current incentive structure for PBMs, according to the DRUG Act’s sponsors, encourages them to drive up the list price of drugs to increase profits.    

‘Pharmacy benefit managers (PBMs) have excessive influence over the prices patients pay at the pharmacy counter,’ said Miller-Meeks. ‘Local Iowa pharmacies are closing due to greedy PBM practices, impacting proximity and access to medications for Iowans. The DRUG Act will put downward pressure on prescription drug prices and insurance premiums by removing the incentive for PBMs to drive up the list price of medications.’

According to the Iowa Pharmacy Association, PBMs have been using opaque reimbursement models that often pay back pharmacies less than the list cost of a drug and the services provided to dispense it. 

As a result of these practices, pharmacies in Iowa and across the country have been forced to close, the association said in a January report. Twenty-nine Iowa pharmacies and 2,300 pharmacies nationwide closed their doors in 2024, according to the association.  

While PBMs have played important roles in making drugs more widely available, through decades of mergers and acquisitions, the three largest PBMs now manage nearly 80% of all prescriptions filled in the U.S., according to a 2024 report from the Federal Trade Commission. 

The DRUG Act’s reforms serve to address this anti-competitiveness, which the bill’s sponsors say will also help lower costs.

‘Pharmacy Benefit Managers (PBMs) contribute to high drug costs because they are incentivized to steer patients towards drugs that are more profitable for PBMs, but may be less clinically effective for consumers,’ said Rep. Nannette Barragán, D-Calif., one of the bill’s co-sponsors. ‘This broken system disproportionately harms low-income individuals, seniors, and those with chronic illnesses who rely on life-saving prescriptions to manage their health.’

Rep. Donald Norcross, D-N.J., another co-sponsor of the DRUG Act, said families in his district ‘are crying out for relief from high prescription drug prices.’

‘Americans deserve access to quality health care and affordable prescription drugs,’ Norcross said. ‘The DRUG Act reins in prescription drug prices by removing the incentive for pharmacy benefit managers to drive up costs, increasing transparency and prioritizing patients over profits.’

This post appeared first on FOX NEWS
0
FacebookTwitterGoogle +Pinterest
previous post
Trump doesn’t use autopen for legally binding documents, unlike Biden, White House says
next post
Vance knocks globalization’s ‘cheap labor’ and lauds ‘America’s great industrial comeback’ at AI summit

You may also like

2024 battle for Senate majority: These five seats...

November 19, 2023

Elon Gets FACT CHECKED On His Own Tweet,...

December 15, 2022

Belk scrubs website of kids’ LGBTQ apparel after...

June 2, 2023

Trump’s ‘big, beautiful bill’ faces setback as Senate...

June 26, 2025

Shock Poll: Nearly Eight of Ten Americans Believe...

October 30, 2022

Trump merchandise outsells pro-Harris by striking margin, as...

October 29, 2024

Failed Biden nominee quietly appointed to top role...

September 19, 2023

Trump rally-goers refuse to waver support for former...

August 14, 2023

JUST IN: Democrat Rep. Mary Peltola Wins Reelection...

November 24, 2022

What James Carville doesn’t get about voter priorities

July 25, 2025

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Bill Gates met with Trump to talk ‘importance of US global health programs and health research’: spox

      August 28, 2025
    • Trump asks SCOTUS to uphold freeze on billions in USAID payments

      August 27, 2025
    • Three Years of Sounding the Debt Alarm at Cato and on the Debt Dispatch

      August 27, 2025
    • Trump Administration Rightly Attacks EU Tech Regulations but Tariffs and Censorship at Home Harm Americans 

      August 27, 2025
    • White House demands all Gaza hostages return home ‘this week’ amid stalled talks

      August 27, 2025
    • Bankruptcy, Hell, and Exit Barriers

      August 27, 2025

    Categories

    • Business (8,897)
    • Investing (2,246)
    • Politics (16,502)
    • Stocks (3,228)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: futureretirementsuccess.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 futureretirementsuccess.com | All Rights Reserved